Cindy L. Carmack, PhD | Authors

Commentary (Basen-Engquist/Cohen): Quality of Life in Low-Grade Non-Hodgkin’s Lymphoma

May 01, 1998

Cancer treatment often has debilitating effects on the patients who receive it. Chemotherapy regimens can produce toxicities, such as gastrointestinal disturbances, hematologic deficiencies, fatigue, and neurotoxicity. Patients typically undergo these chemotherapy regimens to increase their disease-free survival time. Given that these therapies can negatively affect a patient’s quality of life (QOL), treatments need to provide clear curative potential and/or survival benefits to offset detrimental effects on QOL.